公开(公告)号：US20240294634A1

公开(公告)日：2024-09-05

申请号：US17768484

申请日：2020-10-13

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K2039/507

Abstract: This invention relates to the use of a NKG2A-neutralizing agent and an antibody that inhibits human ILT2 to treat cancer, particularly a head and neck squamous cell carcinoma (HNSCC), a lung cancer, optionally an NSCLC, a renal cell carcinoma, a colorectal carcinoma, a urothelial cancer or an ovarian cancer.

公开(公告)号：US20240270865A1

公开(公告)日：2024-08-15

申请号：US18020955

申请日：2021-08-06

Applicant: INNATE PHARMA

Inventor： LAURENT GAUTHIER ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  A61K31/337 ,  A61K39/00 ,  A61P35/00 ,  C07K16/32

CPC classification number: C07K16/2896 ,  A61K31/337 ,  A61P35/00 ,  C07K16/32 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76

Abstract: The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.

公开(公告)号：US20220025056A1

公开(公告)日：2022-01-27

申请号：US17418269

申请日：2019-12-20

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20180030144A1

公开(公告)日：2018-02-01

申请号：US15551919

申请日：2016-02-19

Applicant: INNATE PHARMA

Inventor： STEPHANIE CHANTEUX ,  CARINE PATUREL ,  IVAN PERROT ,  LAURENT GAUTHIER

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2896 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C12Y301/03005

Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US20190071514A1

公开(公告)日：2019-03-07

申请号：US16084249

申请日：2017-03-14

Applicant: INNATE PHARMA ,  OREGA BIOTECH

Inventor： LAURENT GAUTHIER ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.

公开(公告)号：US20220025045A1

公开(公告)日：2022-01-27

申请号：US17418271

申请日：2019-12-20

Applicant: INNATE PHARMA

Inventor： OLIVIER BENAC ,  STÉPHANIE CHANTEUX ,  IVAN PERROT ,  BENJAMIN ROSSI ,  NICOLAS VIAUD

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.

公开(公告)号：US20190225703A1

公开(公告)日：2019-07-25

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： CHRISTOPHE CAUX ,  LAURENT GAUTHIER ,  NICOLAS GOURDIN ,  CHRISTINE MENETRIER-CAUX ,  CARINE PATUREL ,  IVAN PERROT

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.

公开(公告)号：US20180237536A1

公开(公告)日：2018-08-23

申请号：US15517991

申请日：2015-10-09

Applicant: INNATE PHARMA

Inventor： IVAN PERROT ,  CARINE PATUREL ,  LAURENT GAUTHIER

IPC: C07K16/28

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.